Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens
2025 ASCO Annual Meeting
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with extensive-stage small cell lung cancer (SCLC) (Abstract TPS8127).
The ASCO Post Staff
Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual Meeting.
The ASCO Post Staff
Sara M. Tolaney, MD, MPH, FASCO, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings from the phase III ASCENT-04/KEYNOTE-D19 study, which compared sacituzumab govitecan-hziy plus pembrolizumab vs chemotherapy plus pembrolizumab in previously untreated patients with PD-L1–positive advanced triple-negative breast cancer (TNBC) (LBA109).
The ASCO Post Staff
Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, reviews results of the NeoADAURA trial, which looked at neoadjuvant osimertinib with or without chemotherapy vs chemotherapy alone in patients with resectable EGFR-mutated non–small cell lung cancer (NSCLC) (Abstract 8001).
The ASCO Post Staff
Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating tumor and cell-free DNA levels in adults with glioblastoma (Abstract TPS2094).
The ASCO Post Staff
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001).
